+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Allogeneic Cell Therapy Market by Type, Application, End-Use - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5967517
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Allogeneic Cell Therapy Market grew from USD 2.04 billion in 2023 to USD 2.31 billion in 2024. It is expected to continue growing at a CAGR of 13.90%, reaching USD 5.08 billion by 2030.

Allogeneic cell therapy is a revolutionary approach in regenerative medicine, focusing on using donor-derived cells for therapeutic purposes. It holds great promise in treating a variety of immune-related, genetic, and degenerative diseases owing to its potential for mass production and off-the-shelf availability. The necessity of allogeneic therapy stems from its ability to bypass the limitations of autologous therapies, which are often hindered by compatibility issues and lengthy preparation times. Its applications are diverse, spanning across oncology, cardiovascular diseases, musculoskeletal disorders, and autoimmune diseases. The end-use sectors primarily include healthcare services providers, research laboratories, and pharmaceutical companies. Market growth is driven by advancements in cell engineering technologies, increasing prevalence of chronic diseases, and supportive regulatory landscape, which are creating a robust ecosystem for innovation. Key growth opportunities emerge from collaborations between academic institutions and biotech firms aiming to enhance the efficacy and safety profiles of allogeneic therapies. Governments and private firms are increasingly investing in research and infrastructure development, providing a fertile ground for pioneering applications in personalized medicine. However, the market faces significant challenges such as high costs, ethical concerns, and stringent regulatory scrutiny, which can hinder widespread adoption. The complexity of cell sourcing and variability in donor material also pose limitations. For sustained growth, companies should focus on developing standardized manufacturing protocols and improving supply chain efficiencies. Innovations could revolve around better genetic engineering techniques to mitigate immune rejection and advancements in cell preservation technologies. The market is characterized by rapid technological advancements, with a growing number of startups venturing into novel therapies. It remains competitive, driven by a need for constant R&D to maintain a cutting edge. Emphasizing patient safety and addressing regulatory hurdles will be crucial in realizing the full potential of allogeneic cell therapies for broad clinical application.

Understanding Market Dynamics in the Allogeneic Cell Therapy Market

The Allogeneic Cell Therapy Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Growing incidences of cancers, autoimmune diseases, and cardiovascular conditions
    • Favorable government policies and increased funding for research in cell-based therapies
  • Market Restraints
    • Complex regulatory environment for development and administration of allogeneic cell therapies
  • Market Opportunities
    • Development of personalized allogeneic cell therapy solutions
    • Exploration into the new treatment avenues in neurodegenerative diseases and cardiac diseases
  • Market Challenges
    • Immune rejection and compatibility issues

Exploring Porter’s Five Forces for the Allogeneic Cell Therapy Market

Porter’s Five Forces framework further strengthens the insights of the Allogeneic Cell Therapy Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Allogeneic Cell Therapy Market

External macro-environmental factors deeply influence the performance of the Allogeneic Cell Therapy Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Allogeneic Cell Therapy Market

The Allogeneic Cell Therapy Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Allogeneic Cell Therapy Market

The Allogeneic Cell Therapy Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Allogeneic Cell Therapy Market

The Allogeneic Cell Therapy Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Allogeneic Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., AlloSource, Anterogen.Co., Ltd., Atara Biotherapeutics by FUJIFILM Diosynth Biotechnologies, Athersys Inc., Biorestorative Therapies Inc., Biosolution Co., Ltd., Bloodworks Northwest, Brainstorm Cell Limited, Caribou Biosciences, Fate Therapeutics, Gamida Cell, Hope Biosciences, JCR Pharmaceuticals Co., Ltd., Mallinckrodt Pharmaceuticals, MEDIPOST Co., Ltd., Mesoblast Ltd., NuVasive Inc. by Globus Medical, RTI Surgical, Smith+Nephew PLC, Stempeutics Research Pvt. Ltd., Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Tego Science Inc., and ViaCyte Inc. by Vertex Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Allogeneic Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Chimeric Antigen Receptor T Cell Therapy
    • Hematopoietic Stem Cell Transplantation
    • Induced Pluripotent Stem Cell Therapy
    • Mesenchymal Stem Cell Therapy
  • Application
    • Hematological Disorders
    • Oncology
    • Regenerative Medicine
    • Solid Organ Transplantation
  • End-Use
    • Biotechnology & Pharmaceutical Companies
    • Hospitals & Clinics
    • Research Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing incidences of cancers, autoimmune diseases, and cardiovascular conditions
5.1.1.2. Favorable government policies and increased funding for research in cell-based therapies
5.1.2. Restraints
5.1.2.1. Complex regulatory environment for development and administration of allogeneic cell therapies
5.1.3. Opportunities
5.1.3.1. Development of personalized allogeneic cell therapy solutions
5.1.3.2. Exploration into the new treatment avenues in neurodegenerative diseases and cardiac diseases
5.1.4. Challenges
5.1.4.1. Immune rejection and compatibility issues
5.2. Market Segmentation Analysis
5.2.1. Type: Growing adoption of mesenchymal stem cell therapy due to anti-inflammatory and immunomodulatory properties
5.2.2. Application: Revolutionizing allogeneic cell therapy's role in treating and improving organ transplantation procedures
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Allogeneic Cell Therapy Market, by Type
6.1. Introduction
6.2. Chimeric Antigen Receptor T Cell Therapy
6.3. Hematopoietic Stem Cell Transplantation
6.4. Induced Pluripotent Stem Cell Therapy
6.5. Mesenchymal Stem Cell Therapy
7. Allogeneic Cell Therapy Market, by Application
7.1. Introduction
7.2. Hematological Disorders
7.3. Oncology
7.4. Regenerative Medicine
7.5. Solid Organ Transplantation
8. Allogeneic Cell Therapy Market, by End-Use
8.1. Introduction
8.2. Biotechnology & Pharmaceutical Companies
8.3. Hospitals & Clinics
8.4. Research Institutes
9. Americas Allogeneic Cell Therapy Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Allogeneic Cell Therapy Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Allogeneic Cell Therapy Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Getinge's Strategic Partnership with CellRev to Revolutionize Allogeneic Cell Therapy Manufacturing
12.3.2. StemCyte's Pioneering Agreement for Advancing Worldwide Access to Groundbreaking Cord Blood-Derived Cell Therapies
12.3.3. FDA Approval of Gamida Cell's Omisirge Therapy as Transformative Leap in Hematological Cancer Treatment
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ALLOGENEIC CELL THERAPY MARKET RESEARCH PROCESS
FIGURE 2. ALLOGENEIC CELL THERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ALLOGENEIC CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. ALLOGENEIC CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ALLOGENEIC CELL THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ALLOGENEIC CELL THERAPY MARKET DYNAMICS
TABLE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 31. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 33. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 34. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 35. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 36. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 43. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 44. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 46. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 47. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 48. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 49. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 51. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 52. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 57. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 59. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 61. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 65. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 67. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 70. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 73. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 75. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 79. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 85. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 86. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 88. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 89. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 91. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 92. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 94. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 95. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 97. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 98. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 101. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 103. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 104. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 107. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 112. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 113. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 115. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 116. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 118. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 130. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 134. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 139. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 140. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 148. ALLOGENEIC CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
TABLE 149. ALLOGENEIC CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Allogeneic Cell Therapy Market, which are profiled in this report, include:
  • Abeona Therapeutics Inc.
  • AlloSource
  • Anterogen.Co., Ltd.
  • Atara Biotherapeutics by FUJIFILM Diosynth Biotechnologies
  • Athersys Inc.
  • Biorestorative Therapies Inc.
  • Biosolution Co., Ltd.
  • Bloodworks Northwest
  • Brainstorm Cell Limited
  • Caribou Biosciences
  • Fate Therapeutics
  • Gamida Cell
  • Hope Biosciences
  • JCR Pharmaceuticals Co., Ltd.
  • Mallinckrodt Pharmaceuticals
  • MEDIPOST Co., Ltd.
  • Mesoblast Ltd.
  • NuVasive Inc. by Globus Medical
  • RTI Surgical
  • Smith+Nephew PLC
  • Stempeutics Research Pvt. Ltd.
  • Sumitomo Pharma Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Tego Science Inc.
  • ViaCyte Inc. by Vertex Pharmaceuticals

Methodology

Loading
LOADING...

Table Information